Tag Archives: Breast

Pfizer’s Ibrance kisses early breast cancer hopes goodbye with second study failure

After Pfizer’s Ibrance failed a crucial study in HR-positive, HR-negative postsurgery breast cancer patients, the company clung to hope that it could still show a benefit in a high-risk subset of those patients. But new data have officially snuffed out those hopes. There’s “no saving adjuvant for Ibrance,” SVB Leerink analyst Geoffrey Porges wrote in… Read More »

Drug-therapy combo cuts breast cancer recurrence risk by 25%, Eli Lilly announces

Eli Lilly and Company on Sunday announced positive results in the fight against breast cancer. A drug called Verzenio, also known as abemaciclib, in combination with adjuvant endocrine therapy, was said to “significantly” reduce the risk of breast cancer recurrence by 25% for those with a common subtype of breast cancer. The combo treatment also lowered the risk… Read More »

FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer

FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer Print this page South San Francisco, CA — June 29, 2020 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Phesgo, a fixed-dose combination (FDC) of Perjeta® (pertuzumab)… Read More »

Can yoga reduce breast size

Wall press is a good exercise to begin with, not just for the beginners, but for those practitioners at all levels. However, this is a difficult yoga exercise, and you must do this only in the presence of a yoga teacher or professional instructor. Does Ustrasana yoga reduce breast size? Having Frequent Headaches? The Half… Read More »

FDA Approves Tukysa (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

FDA Approves Tukysa (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer Print this page BOTHELL, Wash.–(BUSINESS WIRE) April 17, 2020 — Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) granted approval to Tukysa™ (tucatinib) tablets in combination with trastuzumab and capecitabine for adult patients with advanced unresectable… Read More »